Patents by Inventor Shuyang He
Shuyang He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230355759Abstract: Provided herein are populations of placental-derived natural killer cells comprising a cleavage resistant CD16. Also provided are methods of treating diseases, disorders or conditions in a human subject comprising administering to the subject an effective amount of a population of placental-derived natural killer cells comprising a cleavage resistant CD16 to the subject so as thereby to provide an effective treatment of the to the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The diseases, disorders or conditions include cancers such as multiple myeloma and lymphoma. The present invention also provides compositions comprising populations of placental-derived natural killer cells comprising a cleavage resistant CD16 for the treatment of a subject and methods of their use.Type: ApplicationFiled: July 31, 2020Publication date: November 9, 2023Applicant: CELULARITY INC.Inventors: Xuan GUO, Srinivas SOMANCHI, Rohit MATHUR, Shuyang HE, Qian YE, Xiaokui ZHANG, Salvatore ROTONDO, Hemlata RANA, Weifang LING, James W. EDINGER, Robert J. HARIRI, Andrea DIFIGLIA
-
Publication number: 20230302058Abstract: Provided herein are methods of using tissue culture plastic-adherent placental adherent cells, e.g. placental stem cells, referred to herein as placental adherent cells, to treat lymphedema and lymphedema-related disorders.Type: ApplicationFiled: May 25, 2023Publication date: September 28, 2023Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Shuyang HE
-
Publication number: 20230210909Abstract: Provided herein are methods of using CD10+, CD34?, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of SARS-CoV-2 related acute respiratory failure and ARDS (COVID-19).Type: ApplicationFiled: May 10, 2021Publication date: July 6, 2023Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Xiaokui ZHANG, Shuyang HE, Kathy KARASIEWICZ-MENDEZ, Qian YE, Tanel MAHLAKOIV, Stacy HERB, Corey CASPER
-
Publication number: 20230181649Abstract: The present invention provides method of treating diseases, disorders and conditions in a human subject comprising administering to the subject a population of exosomes or a composition comprising a population of exosomes, wherein said population of exosomes is positive for CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, SSEA-4, or combinations thereof. Such diseases, disorders and conditions include lung, liver, central nervous system, kidney, cardiovascular, gastrointestinal, spleen, eye, systemic and ageing associated diseases, disorders, and conditions.Type: ApplicationFiled: June 19, 2020Publication date: June 15, 2023Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Xiaokui ZHANG, Qian YE, Bhavani STOUT, Haley M. HARIRI, Navjot SHAH, Srinivas Somanchi, Shuyang He
-
Publication number: 20220273716Abstract: Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) to the subject so as thereby to provide an effective treatment of the cancer in the subject. The cells, such as CYNK cells, can be placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and lymphoma. The present invention also provides compositions comprising human placental-derived natural killer cells comprising a CD38 chimeric antigen receptor (CAR) or the treatment of multiple myeloma and lymphoma and methods of their use.Type: ApplicationFiled: July 27, 2020Publication date: September 1, 2022Applicant: Celularity Inc.Inventors: Srinivas SOMANCHI, Xuan GUO, Shuyang HE, Rohit MATHUR, Xiaokui ZHANG, Hemlata RANA, Weifang LING, James W. EDINGER, Robert J. HARIRI, Andrea DIFIGLIA
-
Publication number: 20220265712Abstract: Provided herein are methods of treating cancer in a human subject comprising administering to the subject an effective amount of CYNK cells to the subject so as thereby to provide an effective treatment of the cancer in the subject. The CYNK cells can be placental-derived natural killer (NK) cells or placental CD34+ cell-derived natural killer (NK) cells. The cancers to be treated include multiple myeloma and acute myeloid leukemia. The present invention also provides compositions comprising CYNK cells for the treatment of multiple myeloma and acute myeloid leukemia and methods of their use.Type: ApplicationFiled: June 15, 2020Publication date: August 25, 2022Applicant: Celularity Inc.Inventors: Robert J. Hariri, Xiaokui Zhang, Nassir HABBOUBI, Catherine Balint, Erica Rave, Christopher Keller, Solveig Ericson, Sharmila Koppisetti, Stacy Herb, William van der Touw, Shuyang He, Junhong Zhu
-
Publication number: 20220160787Abstract: The present invention provides an isolated non-human placenta derived stem cell, wherein the stem cell expresses CD90 or wherein the stem cell expresses CD29. The present invention also provides a composition comprising an isolated non-human placenta derived stem cell of the invention or a population of isolated non-human placenta derived stem cells of the invention, and a carrier. The present invention also provides a composition of the invention for use in the manufacture of a medicament to reduce the incidence of rejection in a patient receiving a xenotransplant form a non-human donor. The present invention provides a method of treating a subject receiving a xenotransplant or xenotransfusion comprising the step of administering to the patient an effective amount of a non-human placenta derived stem cells.Type: ApplicationFiled: March 16, 2020Publication date: May 26, 2022Applicant: Celularity Inc.Inventors: QIAN YE, Joseph GLEASON, Lin KANG, Robert J. HARIRI, Shuyang HE, Xiaokui ZHANG, Valentina ROUSSEVA
-
Publication number: 20220000919Abstract: Provided herein are methods of using populations of natural killer (NK) cells and/or ILC3 cells derived from a population of hematopoietic stem or progenitor cells in methods for treating a viral infection, e.g., a coronavirus infection.Type: ApplicationFiled: January 29, 2021Publication date: January 6, 2022Applicant: Celularity Inc.Inventors: Lin KANG, William VAN DER TOUW, Vanesssa VOSKINARIAN-BERSE, Xuan GUO, Robert J. HARIRI, Xiaokui ZHANG, Catherine BALINT, Nassir HABBOUBI, Stacy HERB, Sharmila KOPPISETTI, Tanel MAHLAKOIV, Bhavani STOUT, Junhong ZHU, Corey CASPER, Shuyang HE
-
Publication number: 20210289769Abstract: Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.Type: ApplicationFiled: June 7, 2021Publication date: September 23, 2021Applicant: Celularity Inc.Inventors: Andy ZEITLIN, Gregory RUSSOTTI, Shuyang HE, Ajai PAL, Hong CHEN, Thomas BRIEVA, Ryan SHORR, Brian MURPHY
-
Publication number: 20190314424Abstract: Provided herein are methods of using tissue culture plastic-adherent placental adherent cells, e.g. placental stem cells, referred to herein as placental adherent cells, to treat lymphedema and lymphedema-related disorders.Type: ApplicationFiled: December 6, 2017Publication date: October 17, 2019Applicant: CELULARITY, INC.Inventors: Robert J. Hariri, Shuyang He
-
Publication number: 20190261623Abstract: Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.Type: ApplicationFiled: September 21, 2018Publication date: August 29, 2019Applicant: CELULARITY, INC.Inventors: Andy Zeitlin, Gregory Russotti, Shuyang He, Ajai Pal, Hong J. Chen, Thomas Brieva, Thomas Brieva, Bryan Murphy
-
Publication number: 20190093081Abstract: Provided provided herein are methods of treating a subject having a brain tumor, e.g., a glioblastoma by administering to the subject an effective amount of a cell population comprising human placenta-derived natural killer cells. Also provided are methods of suppressing the growth of brain tumor cells comprising contacting the glioblastoma cells with an effective amount of a cell population comprising human placenta-derived natural killer cells. Further provided are compositions comprising subject an effective amount of a cell population comprising human placenta-derived natural killer cells for use in the treatment of a brain tumor in a subject or for use in the manufacture of a medicament for treatment of a brain tumor in a subject.Type: ApplicationFiled: September 28, 2018Publication date: March 28, 2019Applicant: CELULARITY, INC.Inventors: Lin KANG, Xiaokui ZHANG, William VAN DER TOUW, Robert J. HARIRI, Shuyang HE
-
Patent number: 10104880Abstract: Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.Type: GrantFiled: August 20, 2009Date of Patent: October 23, 2018Assignee: CELULARITY, INC.Inventors: Andy Zeitlin, Gregory Russotti, Shuyang He, Ajai Pal, Hong J. Chen, Thomas Brieva, Ryan Shorr, Brian Murphy
-
Publication number: 20100047213Abstract: Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.Type: ApplicationFiled: August 20, 2009Publication date: February 25, 2010Inventors: Andy Zeitlin, Gregory Russotti, Shuyang He, Ajai Pal, Hong J. Chen, Thomas Brieva, Ryan Shorr, Brian Murphy